Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

NCT06934642 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of tirzepatide on liver-related health markers in adults with both obesity and MASLD.

Status Recruiting Currently enrolling participants.

Phase Early Phase 1 First exploratory testing in people.

Type Interventional (clinical trial)

Design open-label (no blinding) study

Participants 8 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2025-06 · est. completion 2026-08

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06934642 ↗

Description as written by the study sponsor.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity. It has also been shown to help with MASLD. The purpose of this study is to study how tirzepatide affects the liver in patients with MASLD. Participants will be asked to: * Take tirzepatide for 12 months. * Come in for clinic visits every 3 months. * Have blood drawn at baseline, 6, and 12 months. * Complete a liver ultrasound at baseline and at 12 months.

Treatments tested

Tirzepatide also known as Zepbound, Mounjaro Drug

The drug is being studied to better understand the biological effects of tirzepatide on MASLD.

Main thing measured	Biomarkers associated with MASLD
Sponsor	University of New Mexico
Conditions studied	MASLD, Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06934642 ↗